Kymera Therapeutics, Inc.
KYMR
Positions held
Your positionsKYMR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Kymera Therapeutics is positioned in the biotechnology sector, focusing on innovative therapies that target disease mechanisms, which could lead to significant advancements in treatment options.
- Revenue increased by 89% compared to the prior quarter, reaching $65 million.
- The operating margin improved to -116.3%, indicating a positive trend in operational efficiency.
- The company faces challenges with a high debt-to-equity ratio of 5.205, which may limit financial flexibility.
- Net income remains negative at -61.211 million for the latest quarter, reflecting ongoing financial struggles.
- The profit margin is currently at -2.85%, highlighting the need for improved profitability strategies.
Fundamentals
| Market cap | $8.99B | Enterprise value | $8.48B | Trailing P/E | — | Forward P/E | -21.49 |
| PEG | — | Price / book | 6.00 | Beta | 1.98 | Dividend yield | 0.00% |
| Revenue growth | 4.7% | Earnings growth | — | Gross margin | -2.6% | Operating margin | -116.3% |
| Profit margin | -2.9% | ROE | -24.2% | ROA | -15.6% | Debt / equity | 0.05 |
| Current ratio | 10.34 | Free cash flow | -$144.07M | Analyst recommendation | strong_buy | Mean target | $139.32 |
| 52w high | $130.05 | 52w low | $55.26 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $65.0M | $34.4M | $2.9M | $2.8M | $11.5M | — |
| Op margin | -116.3% | -244.9% | -3411.0% | -3207.9% | -736.8% | — |
| Net income | -$61.2M | -$69.2M | -$87.0M | -$82.2M | -$76.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$75.6M | -$84.2M | -$97.9M | -$88.7M | -$84.6M | — |
- Revenue +89% vs prior quarter ($65M vs $34M).
- Operating margin expanded to -116.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M |
| Op margin | -881.2% | -545.4% | -210.6% | -344.4% |
| Net income | -$311M | -$224M | -$147M | -$155M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$346M | -$257M | -$166M | -$161M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123
2026-09-04 · Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
2026-09-03 · Can KT-621 Mark a Turning Point for Kymera Therapeutics?
2026-09-02 · Kymera Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-02 · Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
2026-08-12 · Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
2026-08-10 · Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
2026-08-06 · KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
2026-08-06 · Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)
2026-08-05 · Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-05 · Kymera Therapeutics Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns